Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7862]

ASCO GI 2022: Ripretinib demonstrates comparable efficacy and fewer side effects compared to sunitinib in patients with GIST previously treated with imatinib

ASCO GI 2022: Ripretinib demonstrates comparable efficacy and fewer side effects compared to sunitinib in patients...

Newly discovered DNA repair mechanisms point to potential therapy targets for cancer and neurodegenerative diseases

Newly discovered DNA repair mechanisms point to potential therapy targets for cancer and neurodegenerative diseases

Scientists demonstrate utility of bilateral tumour model for evaluating anti-cancer T-cell responses

Scientists demonstrate utility of bilateral tumour model for evaluating anti-cancer T-cell responses

ASCO GI 2022: Durvalumab plus tremelimumab significantly improves survival for patients with advanced liver cancer compared to sorafenib

ASCO GI 2022: Durvalumab plus tremelimumab significantly improves survival for patients with advanced liver cancer...

ASCO GI 2022: Durvalumab significantly improves survival for patients with biliary tract cancer compared to chemotherapy alone

ASCO GI 2022: Durvalumab significantly improves survival for patients with biliary tract cancer compared to...

ASCO GI 2022: Pembrolizumab significantly improved OS versus placebo in certain patients with advanced HCC previously treated with sorafenib

ASCO GI 2022: Pembrolizumab significantly improved OS versus placebo in certain patients with advanced HCC...

Combination therapies may improve outcomes due to independent, rather than synergistic or additive, drug action

Combination therapies may improve outcomes due to independent, rather than synergistic or additive, drug action

Matched targeted treatment based on ESCAT actionable genomic alterations associates with improved prognosis of cholangiocarcinoma patients

Matched targeted treatment based on ESCAT actionable genomic alterations associates with improved prognosis of...

New treatment target ID’d for radiation-resistant cervical cancer

New treatment target ID’d for radiation-resistant cervical cancer

Researchers make important new findings about how to test cancer-fighting drugs

Researchers make important new findings about how to test cancer-fighting drugs

More from ecancer